Balancing Early Promise and Significant Uncertainty: Maintaining a Hold on Acrivon Therapeutics Amid Limited Data and Long-Dated Clinical Risk

JonesTrading analyst Soumit Roy has maintained their neutral stance on ACRV stock, giving a Hold rating today.

Soumit Roy has given his Hold rating due to a combination of factors related to both promise and uncertainty in Acrivon Therapeutics’ development program. While the updated data for ACR-368 in second- and third-line serous endometrial cancer show encouraging response rates versus historical outcomes, the results are based on a relatively small patient group, making it difficult to reliably project performance in a larger, more diverse population. He expects that response rates will likely decline as the trial scales up, which could reduce the likelihood of showing a clear advantage over existing treatment options. In addition, key strategic questions remain unresolved, including whether the company will ultimately pursue an all-comer strategy or concentrate on biomarker-positive patients only, and how regulators will view the overall probability of success.

Soumit Roy also highlights that, despite the absence of a well-defined standard of care in this late-line setting and the theoretical path to accelerated approval if robust response rates can be maintained, the program is still in an early and evolving phase. The pivotal Phase 2b arm evaluating ACR-368 with ultra-low-dose gemcitabine will not generate initial data until around mid-2026, leaving a long period of execution and clinical risk ahead. Given the modest data advantage so far, the limited target population (serous subtype representing a small fraction of endometrial cancer), and the number of outstanding clinical and regulatory uncertainties, he concludes that it is premature to adopt a more constructive stance. As a result, he remains on the sidelines with a Hold recommendation until more mature and confirmatory data are available.

According to TipRanks, Roy is an analyst with an average return of -13.5% and a 25.30% success rate. Roy covers the Healthcare sector, focusing on stocks such as Cullinan Management, CervoMed, and Enliven Therapeutics.

In another report released today, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $3.00 price target.